Cyclic indoor daylight photodynamic therapy

  • Research type

    Research Study

  • Full title

    Cyclic indoor daylight photodynamic therapy (DL-PDT) in high-risk organ transplant recipients for the prevention of actinic keratosis and non-melanoma skin cancers

  • IRAS ID

    357561

  • Contact name

    Sumir Chawla

  • Contact email

    sumir.chawla@nhs.net

  • Sponsor organisation

    Imperial College Healthcare NHS Trust

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Organ transplant recipients (OTRs) face a significantly higher risk of developing certain skin cancers, particularly non-melanoma skin cancers such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). This increased risk can be due to the long-term use of medications that suppress the immune system, which are necessary to prevent organ rejection. Over time, these patients are more likely to develop precancerous skin lesions, such as actinic keratosis (AK), which can progress to more serious cancers if not treated early.
    Current treatments for these skin conditions, including freezing techniques, topical creams, and surgery, have limitations, especially in patients with large areas of affected skin or need for repeated treatments. Photodynamic therapy (PDT) is an established treatment that uses a special cream activated by light to target and destroy abnormal skin cells. It has shown promise in treating and preventing skin cancers in OTRs, but traditional PDT can be painful, and the less painful daylight PDT be limited by weather and external factors.
    This study will explore the use of indoor daylight photodynamic therapy (DL-PDT), which simulates sunlight in a controlled environment, as a way to prevent the development of AK and skin cancers in high-risk OTR patients. The treatment is expected to be more comfortable for patients and easier to administer year-round. By investigating the safety and effectiveness of cyclic DL-PDT, the study aims to find a better way to prevent skin cancers in this vulnerable group of patients, potentially improving their long-term outcomes.

  • REC name

    London - Surrey Research Ethics Committee

  • REC reference

    25/LO/0515

  • Date of REC Opinion

    1 Sep 2025

  • REC opinion

    Further Information Favourable Opinion